| Date | Title | Description |
| 25.06.2025 | 2025 WEF Technology Pioneers highlight two Swiss Startups |
Celebrating its 25th anniversary this year, the World Economic Forum’s Technology Pioneers programme community helps early-stage start-ups with technologies that can positively shape our future to grow. Since 2000, the initiative has recog... |
| 03.06.2025 | Un jubilé synonyme de renaissance |
Le 25e anniversaire du service de valorisation de la recherche de la CHUV et de l'UNIL a été célébré au Biopôle, dans le nouvel auditorium SE-C, en présence d'une communauté enthousiaste de chercheurs, de start-ups et de représentants d'en... |
| 08.05.2025 | HAYA Therapeutics: Pioneering the Future of RNA-Guided Therapies | In the world of biotechnology, innovation is the lifeblood. HAYA Therapeutics has just secured a hefty $65 million in Series A funding, a financial boost that could change the landscape of chronic and age-related disease treatment. This fun... |
| 08.05.2025 | HAYA Therapeutics Raises $65M in Series A Funding | Haya Therapeutics, a Lausanne, Switzerland- and San Diego, CA-based biotechnology company pioneering precision RNA-guided regulatory genome targeting therapeutics that reprogram disease-driving cell states for rare, common, chronic and age-... |
| 08.05.2025 | HAYA Therapeutics: $65 Million Series A Closed To Deliver Precision RNA-Guided Medicines | HAYA Therapeutics – a biotechnology company pioneering precision RNA-guided regulatory genome targeting therapeutics that reprogram disease-driving cell states for rare, common, chronic and age-related diseases – announced that the company ... |
| 08.05.2025 | HAYA Therapeutics secures USD 65M to advance RNA-guided therapies for chronic and age-related diseases | Proceeds from the USD 65 million round will fund clinical trials for HTX-001, HAYA Therapeutics's lead candidate for non-obstructive hypertrophic cardiomyopathy (nHCM), and support pipeline expansion into conditions such as pulmonary fibros... |
| 08.05.2025 | HAYA Therapeutics banks $65 million Series A funding |
HAYA Therapeutics is a biotechnology company pioneering precision RNA-guided regulatory genome targeting therapeutics that reprogram disease-driving cell states for rare, common, chronic and age-related diseases. The core of HAYA’s proprie... |
| 06.05.2025 | The Stock Market: A Tug of War Between Optimism and Uncertainty | The stock market is a living organism. It breathes, pulses, and reacts to the world around it. As we step into this week, the atmosphere is thick with anticipation. Wall Street is poised for a lower open, a signal that the calm may be fleet... |
| 05.05.2025 | Recognition for Swiss innovators across the globe |
Haya Therapeutics’ CEO, Samir Ounzain, has been recognized as one of the top innovators in The Medicine Maker Power List, under the “Advanced Medicine” category. Samir focuses on a new area of drug development focused on the regulatory gen... |
| 17.03.2025 | Seasoned executives join Swiss startups |
VertX IQ has welcomed Tamara Jost as our new Chief Technology Officer, bringing a wealth of fintech expertise to drive innovation and enhance the startup’s technology capabilities. Founded in 2020, VertX IQ is a financial services and tech... |
| 17.02.2025 | Healthtech startups set for growth |
The Innosuisse Certificate serves as a mark of excellence, indicating that a company has demonstrated growth and success in competitive markets. To obtain this certification, companies which went through the Innosuisse Start-up Coachingmus... |
| 23.09.2024 | Set for growth: startups rely on experienced leaders |
Anton von Rueden has been appointed as the new CEO of Invenda Group AG, bringing with him a distinguished track record in driving innovation and sustainable growth within the tech industry. Founded in 2017 and employing 100 employees today... |
| 05.09.2024 | HAYA Therapeutics and Lilly: A Game-Changer in Obesity Treatment | In a bold move, HAYA Therapeutics has struck a monumental deal with Eli Lilly, a titan in the pharmaceutical industry. This collaboration, valued at up to $1 billion, aims to tackle obesity and related metabolic disorders through innovative... |
| 04.09.2024 | HAYA Therapeutics secures USD 1 billion deal with Lilly to target obesity through RNA platform | HAYA Therapeutics, a biotechnology company pioneering precision RNA-guided regulatory genome targeting therapeutics for chronic diseases, today announced a multi-year agreement with Eli Lilly and Company to apply HAYA’s advanced RNA-guided ... |
| 04.09.2024 | HAYA Therapeutics wins Major Collaboration with Lilly | Under the terms of the collaboration, HAYA will receive an upfront payment, including an equity investment, and is eligible to receive up to an aggregate $1 billion in pre-clinical, clinical and commercial milestone payments, as well as roy... |
| 27.07.2024 | The Future of Diagnostics: Roche's Vision Unveiled at ADLM 2024 | In the bustling heart of Chicago, Roche is setting the stage for the future of laboratory diagnostics. At the 2024 Association for Diagnostics & Laboratory Medicine (ADLM) Clinical Lab Expo, the company is showcasing a suite of innovati... |
| 23.07.2024 | Erfahrene Expertinnen und Experten verstärken Startup-Management |
Das EHT-Spin-off Riverkin begrüsst mit Nitin Kumar and Marco Adriano Magno zwei neue Mitgründer. Nitin Kumar hat einen Doktortitel in Computational Biology und war an einigen erfolgreichen Startup-Exits beteiligt. Mit diesen Erfahrungen kö... |
| 01.07.2024 | Inaugural European entrepreneur award crowns HAYA Therapeutics Founders |
Recognizing entrepreneurial vision and talent in the life sciences among the DACH region, which includes Germany, Austria and Switzerland, the award honors the efforts of Drs. Ounzain and Blessing in creating a company developing an innova... |
| 14.03.2024 | Swiss Economic Awards: 9 Startups im Finale |
Der Swiss Economic Award gilt als renommierteste Auszeichnung für Jungunternehmen in der Schweiz. Der Award zeichnet herausragende unternehmerische Leistungen in den Kategorien Dienstleistung, Deeptech & Life Science und Produktion &am... |
| 25.01.2024 | ZKB Pionierpreis Technopark shortlists 11 startups |
The Pionierpreis is an initiative by Zürcher Kantonalbank and Technopark Zürich and has been running for more than two decades, promoting outstanding technology startups. The selection of the first startups for the 2024 competition brings ... |
| 07.09.2023 | A biotech company ranks first at the TOP 100 Swiss Startup Award | |
| 14.10.2022 | International and seasoned board members for Switzerland | |
| 08.09.2022 | The TOP 100 Swiss Startup Award 2022 celebrates Switzerland’s most promising startups | |
| 10.02.2022 | New US Laboratory and funding for HAYA Therapeutics | |
| 09.02.2022 | HAYA closes USD 5M seed extension led by Humboldt Fund and establishes U.S. Location | HAYA’s main headquarters and laboratory facilities will remain in Lausanne, Switzerland. The company also announced that it has successfully closed a USD 5 million seed extension led by Humboldt Fund, with participation from existing invest... |
| 21.05.2021 | Haya Therapeutics Closes CHF 18M Funding | Haya Therapeutics, a Lausanne, Switzerland-based company which develops precision medicines that target tissue and cell-specific long non-coding RNAs (lncRNAs), closed a CHF18M funding round.
The round was led by Broadview Ventures, with pa... |
| 20.05.2021 | HAYA Therapeutics closes CHF 18 million seed round | |
| 20.05.2021 | HAYA Therapeutics raises CHF 18 million Seed financing to advance anti-fibrotic therapies targeting long non-coding RNAs | HAYA Therapeutics raises CHF 18 million Seed financing to advance anti-fibrotic therapies targeting long non-coding RNAs 20.05.2021 09:00, Guillaume Tinsel linkedIn facebook twitter instagram youtube -->
HAYA Therapeutics, a company deve... |
| 20.05.2021 | HAYA Therapeutics raises CHF 18 million Seed financing to advance anti-fibrotic therapies targeting long non-coding RNAs | Founded and led by a team of experts in lncRNA biology and fibrotic disease, HAYA will use the funds from the financing to advance the discovery and development of innovative organ and cell-selective therapeutics that target lncRNAs to trea... |
| 20.05.2021 | HAYA Therapeutics closes CHF 18 million seed round | Along side Broadview Ventures, HAYA Therapeutics’ seed round attracted additional investors including Apollo Health Ventures, BERNINA BioInvest, 4See Ventures, Schroder Adveq and Viva BioInnovator. The startup will use the funds from the fi... |
| 25.09.2020 | Swissnex Boston welcomes 12 Swiss startups to its virtual Bootcamp | The startup Bootcamp offers Swiss Startups with the opportunity to travel Boston or New York to prepare for entry into the US Market or to validate their product before they decide to expand. For the first time, startups will simultaneously... |
| 25.09.2020 | Swissnex Boston welcomes 12 Swiss startups to its virtual Bootcamp | |
| 25.11.2019 | Swiss startups on the global radar | |
| 19.09.2019 | CHF 100.000 for Haya Therapeutics | |
| 07.06.2019 | >>venture>> announces nine winners | |
| 15.05.2019 | >>Venture>> finalists to contest for a cash prize of CHF 350000 | |
| 16.08.2018 | CHF130’000 for startups with new heart failure and tissue reconstruction therapies | |
| - | HAYA Therapeutics | “We are leveraging the power of the dark genome to develop precise and potent RNA therapies for disease driving cell-state reprogramming.” |
